West Pharmaceutical Services, Inc. $WST Shares Sold by Assetmark Inc.

Assetmark Inc. trimmed its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 18.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,599 shares of the medical instruments supplier’s stock after selling 2,394 shares during the quarter. Assetmark Inc.’s holdings in West Pharmaceutical Services were worth $2,657,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new position in West Pharmaceutical Services during the 4th quarter valued at $272,041,000. Generation Investment Management LLP raised its stake in shares of West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock worth $429,733,000 after buying an additional 585,855 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock worth $323,280,000 after buying an additional 473,547 shares in the last quarter. Steadfast Capital Management LP acquired a new stake in shares of West Pharmaceutical Services in the third quarter valued at $123,667,000. Finally, AQR Capital Management LLC boosted its stake in West Pharmaceutical Services by 420.1% during the third quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock valued at $142,949,000 after buying an additional 440,929 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at West Pharmaceutical Services

In related news, CAO Chad Winters sold 896 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Price Performance

WST stock opened at $355.25 on Friday. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00. The firm has a 50-day moving average of $336.51 and a two-hundred day moving average of $287.14. The firm has a market capitalization of $25.10 billion, a PE ratio of 47.49, a P/E/G ratio of 2.90 and a beta of 1.16. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.76%.

Analyst Ratings Changes

WST has been the topic of a number of research analyst reports. Evercore reaffirmed an “outperform” rating and set a $410.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 6th. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Stephens reaffirmed an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Finally, Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $363.17.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical beat Q2 expectations, reporting adjusted EPS of $2.37 versus $2.08 expected and revenue of $872.3 million versus $840.0 million expected, showing solid demand across its business. West Reports Second-Quarter 2026 Results
• Positive Sentiment: The company raised full-year 2026 guidance, now expecting EPS of $8.85 to $9.05 and revenue of $3.3 billion to $3.4 billion, both above prior expectations. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
• Positive Sentiment: Management pointed to strong demand for high-value products, including components tied to GLP-1, diabetes, obesity, and biologics drugs, which is helping drive growth and improve investor sentiment. West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
• Neutral Sentiment: The company also issued Q3 guidance slightly above analyst estimates, reinforcing confidence in near-term momentum. West Pharmaceutical Raises 2026 Guidance After Strong Quarter

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.